Detalhe da pesquisa
1.
Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.
Haematologica
; 105(6): e302-e306, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31558675
2.
T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma.
Clin Cancer Res
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38687588
3.
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Blood Adv
; 8(1): 194-206, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052042
4.
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity.
EBioMedicine
; 93: 104663, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379657
5.
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.
Hemasphere
; 7(5): e881, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37153876
6.
Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
J Clin Med
; 10(19)2021 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34640611
7.
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients.
Cancers (Basel)
; 13(10)2021 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34070044
8.
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Sci Transl Med
; 13(623): eabh1962, 2021 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34878825
9.
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma.
Blood Adv
; 5(23): 5128-5139, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625791
10.
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Blood Adv
; 5(8): 2196-2215, 2021 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33890981
11.
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
Oncotarget
; 11(45): 4076-4081, 2020 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33227097
12.
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies.
Cancers (Basel)
; 12(12)2020 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33321969
13.
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.
Clin Cancer Res
; 26(9): 2203-2215, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31969333
14.
CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients.
J Transl Autoimmun
; 2: 100022, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32743508
15.
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Expert Rev Clin Immunol
; 14(3): 197-206, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29465271
16.
Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma.
Hemasphere
; 4(4): e413, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32904033
17.
Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment.
Clin Lymphoma Myeloma Leuk
; 19(1): e9-e11, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30392824
18.
Inconclusive evidence for allergic rhinitis to predict a prolonged or chronic course of acute rhinosinusitis.
Otolaryngol Head Neck Surg
; 150(1): 22-7, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24233061